| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
The effect of pre-treatment with SU5416, a selective VEGF receptor-2 inhibitor, on tumor disposition and in-vivo anti-tumor activity of polyethylene glycol (PEG)-modified liposomal paclitaxel (PL-PTX) was evaluated in two B16 or LLC solid tumor-bearing mice. Pre-treatment with SU5416 significantly enhanced the in-vivo anti-tumor effect of PL-PTX in B16 tumor-bearing mice, but the same treatment did not affect the anti-tumor effect of PL-PTX in LLC tumor-bearing mice at all. Considering that VEGF levels within B16 tumors was found to be about 20-fold higher than that in LLC tumors, it was suggested that SU5416 would be able to normalize tumor vasculatures in certain types of tumor tissue such as B16 where VEGF plays a major role for promoting angiogenesis.
|
